nysemrk
ValueWalk
The biopharmaceutical industry had an exceptional year in 2022 with notable success for those with COVID-19 vaccines. The majority (15) of the top 20 publicly traded global innovative biopharma companies reported a 5.2% growth in the aggregate revenue to $868.97 billion from 2021 to 2022, reveals GlobalData, a leading data and analytics company. Global Biopharma Companies Report YoY GrowthGlobalData reveals that Novo Nordisk (NYSE:NVO), Pfizer (NYSE:PFE) and Merck & Co (NYSE:MRK) reported YoY revenue growth of 25.7%, 23.4% and 21.7%, respectively, in 2022. Pfizer finished first in the top 20 l...
ValueWalk
Shareholders denounce Merck’s lawsuit against HHS as a transparent campaign to protect profits at the expense of patients Shareholders Deem Merck’s Lawsuit Against HHS As UnconstitutionalNEW YORK, NY, THURSDAY, JUNE 8, 2023 – Shareholders of Merck & Co (NYSE:MRK) responded to the news that the company had filed a lawsuit in the DC District Court against the Department of Health and Human Services. The lawsuit cites as “unconstitutional” a key provision of the Inflation Reduction Act that going forward will give Medicare the ability to negotiate better prices for certain high-cost drugs. The in...
ValueWalk
Animal health company Zoetis gapped up after raising 2023 guidance.Wall Street expects double-digit earnings growth this year and next.The stock’s price is outperforming three-quarters of the market in the past year, with especially strong growth in the past three months.5 stocks we like better than ZoetisNext time you take your dog or cat to the vet, there’s a good chance the clinic is using products made by Zoetis Inc. (NYSE:ZTS). Q4 2022 hedge fund letters, conferences and more The stock is up 7.99 in the past week, after topping fourth-quarter views in its February 14 report. It also guide...
ValueWalk
Dow component Merck is within 2% of a new all-time high, after rallying 7.30% in the past month.Merck’s recent rise follows a couple of positive developments in October surrounding a high-blood-pressure treatment and a skin cancer vaccine.Merck reports its third quarter on October 27, with Wall Street eyeing earnings of $1.68 per share on revenue of $14.28 billion.Dow component Merck (NYSE:MRK) is within 2% of a new all-time high, after rallying 7.30% in the past month. Shares closed Tuesday at $94.61, up $0.49, or 0.52% in volume that was 13% heavier than normal. Q3 2022 hedge fund letters, c...
ValueWalk
On the heels of OxyContin maker Purdue Pharma asking a federal judge to approve a $6 billion nationwide settlement due to the overdose and addiction crisis, a new company will form following the U.S. Bankruptcy Court chapter 11 plan of reorganization. The resulting company is known as Knoa Pharma and profits will be used to fight an opioid crisis that has been linked to the deaths of more than 500,000 Americans over the past two decades. Despite the devastating headlines linked to pharmaceuticals, you can still point to dozens of reasons to invest in pharmaceuticals. The global pharmaceuticals...
ValueWalk
Following is the unofficial transcript of a CNBC interview with Merck & Co., Inc. (NYSE:MRK) President & CEO Robert Davis on CNBC’s “TechCheck” (M-F, 11AM-12PM ET) airing today, Monday, January 10. Q4 2021 hedge fund letters, conferences and more Interview With Merck CEO Robert DavisMEG TIRRELL: Now joining us is the Merck CEO Rob Davis. Rob, thanks for being with us around this virtual J.P. Morgan Healthcare Conference. I want to start off by asking you about Molnupiravir, your, your COVID-19 antiviral drug given where we are with the Omicron variant. What kind of demand are you seeing for th...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら